StockData
Artelo Biosciences, Inc. logo

Artelo Biosciences, Inc. (ARTL) stock

ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.68−0.02 (-1.18%)

Close on Nov 17, 2026Market cap $1.13MP/E –Yield –

Earnings

Artelo Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Artelo Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 17, 2026after the close–––Release
Q2 FY2025ended Jun 30, 2025Jul 11, 2025after the close–––Release
Q1 FY2020ended Nov 30, 2019Jan 14, 2020before the open–––Filing
Q3 FY2019ended May 31, 2019Jul 15, 2019after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Artelo Biosciences has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Artelo Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Artelo Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. News
  3. Update
  4. Update
  5. Update
  6. Results
  7. News
  8. Update
  9. Update
  10. Update
  11. Update
  12. Update
  13. Update
  14. Update
  15. Update

See a number that looks wrong?